105 related articles for article (PubMed ID: 15160991)
1. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status.
Chobanian NH; Greenberg VL; Gass JM; Desimone CP; Van Nagell JR; Zimmer SG
Anticancer Res; 2004; 24(2B):539-45. PubMed ID: 15160991
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
Dietrich CS; Greenberg VL; DeSimone CP; Modesitt SC; van Nagell JR; Craven R; Zimmer SG
Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
[TBL] [Abstract][Full Text] [Related]
7. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
8. [Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].
Yang YN; Wang Y; Wang XG; Jiang SJ
Ai Zheng; 2008 Aug; 27(8):816-21. PubMed ID: 18710614
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
[TBL] [Abstract][Full Text] [Related]
10. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Takai N; Ueda T; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
[TBL] [Abstract][Full Text] [Related]
12. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death.
Egler V; Korur S; Failly M; Boulay JL; Imber R; Lino MM; Merlo A
Clin Cancer Res; 2008 May; 14(10):3132-40. PubMed ID: 18483381
[TBL] [Abstract][Full Text] [Related]
14. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
Bevins RL; Zimmer SG
Cancer Res; 2005 Aug; 65(15):6957-66. PubMed ID: 16061681
[TBL] [Abstract][Full Text] [Related]
15. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Ueda T; Takai N; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2007 Feb; 19(2):301-8. PubMed ID: 17203205
[TBL] [Abstract][Full Text] [Related]
16. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
Wahl H; Tan L; Griffith K; Choi M; Liu JR
Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
Sonnemann J; Hüls I; Sigler M; Palani CD; Hong le TT; Völker U; Kroemer HK; Beck JF
Oncol Rep; 2008 Jul; 20(1):219-24. PubMed ID: 18575740
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil.
Johnson KR; Fan W
Anticancer Res; 2002; 22(6A):3197-204. PubMed ID: 12530065
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
